Genmab Announces Financial Results for the First Half of 2021
11/8 17:02
August 1 1 , 20 2 1 ; Copenhagen, Denmark; Interim Report for the First Half of 20 2 1 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application (BLA), for patients with recurrent or metastatic cervical cancer DARZALEX ® net sales increas ed 52%...